Member Info for gyp8

Complete K24 Bull S.

First the UK interntaional court as ruled against Kurdistan on oil with Dana gas. secondly Hawrmi failed again nto present full details and what is more, the PSC signed by IOC after 2003 were deemed ilegal in another court case last year.

The Constitution is flawed as it is, but all parties agreed at outset existing oil field would be callsed as non exploration and that means Tawk Taq, Chia Surkh a d 4 others, ..Hawrmi carving them up into smaller PSC does not alter they wetre existing oil fileds and date back in such detail they are listed under the clinton Administraion of 1996, when it was deemed that the Northern Iraq region was split into two sections due to the Corrupt nature of Barzani working with Saddam Hussiem and murdeing 1000's of Kurds that Barzani did withy Saddam.

Then you have further proof with Galbraith trying toi hide a deal he did for Northern Iraq oil in 2002/2003 when he and his mate hawrmi sold a psc illegally to Norsk Hydro, which resulted in Norsk Hydrom notffying the the UN and making it cleare they had been hoodwinked into signing a illegal psc, which they quickly got out of by paying of Haewrmis mate a nd galbraith, but then Norsk Hydros laywrrs got that money back and its logged under Oslo law, the fact that a sitting representative, a UK kurd and a Norwegian rook had sought to make millions from illegal moves.

Then you have a DNO psc that can be removed if the ICG sought to,, so its a case of the Kurdistan 24 Barxzani rag to rag paper trying to spin it.

Personbally I dont give two hoots about Iraq oil law, but it time the KRG crooks and the IOCs who pay bungs were exposed and cases this year will do that

mnawaz. Its another option for a neurologist to discuss with his or her patients, the benefits may assist, but IMO would depend on the underlyiung cause, such as Chronic Inflammatory Demyelinating Polyneuropathy from (GBS) . No two cases can be the same, but with FDA approval and Nuerologist being prepared to try it as a possible treatment is allivaiting the pain caused, then yes its a step forward.

My view is, it will need a major USA based Hospital that treats 100's of patients on a regular basis to take it on and that would also come down to Patient awareness of the drug and Insurance company approval to cover the cost of each course of treatment.

Either way, any breakthrough pharamcutricals that help find there way to the people who need them.

Maybe the answer on Lupuzor will come when such Hospitals as the John Hopkins as an example are prepared to use it on there patinets, thus giving it the backing of Major Hospitals who are well known and respected to treat certain Neurological, Rheumatological and autoimmune diseases, and it may assit some Cancer patients as well, which is yet to be flagged by Lupuzor

Watch it and be warned as GKP wont get away with it tiwce nor will the corrupt Kurds , sometimes Hawrmi ponzi scheme boys like the thieves who promoted WZR and that one is back in the legal system in the US

N_I the main issue here is they have no need what so ever to refinace any bonds, they simply care the bonds with Cash they have and are owed.

Any new investment to get to 110,000 bopd should come from issuing new shares, that way the company is not beholding to the KRG games of theft and corruptionj which the board seem happy to participate in.

The KRG record on payments is woeful and when a company as one asset - and no one would dispute the asset, then the company must first collect all its owed and refrain from new Debt, and it matters not even if the debt was offered at 0.025% .

WZR was a classic case of corruption and it had its only assets in Kurdistan, even its main shareholders when it was WOSI wanted rid of WZR... They were correct, as WZR burnt its shareholders and jumped right into bed with one of the US most nororious Neocon scammers.

One also as to wonder at Bowleven and its cash in the bank and who its working with/

No Compnay that owed $100's of millions , would ever consider refinancing Bonds , you dont increaaase your debt when your creditor fails to pay.

By all means issue new sahres, but then the question is still the same, this company is a ponzi scheme for the Corrupt KRG and others, and still cant diversify into other areas, so expect to be burnt again and again, only short term traders will make money.

GKP is still subjected to Barzani and Hawrmi games with Illict action that the city of London Regulators dont clamp down on.

When Tawke came on line the IGC MoO paid for the pipelines, not DNO . Suggest some get there facts right

All Side effect have to be published any possible effect as to be, thats how the US is regulated, its not regulated like the UK Lax regulation with MHRA.

Bottom Line Mnawaz, is you dont have a FDA or Europen Aapprovale for Lupuzor , not like the FDA and European approved approved drug like Hizentra that is already approved for "Chronic Inflammatory Demyelinating Polyneuropathy "

Suggest when IMM gain that, its only then that it will be worth considering it use by medical systems worldwide, until then, you still have a drug that failed it phase 3 trail for Lupus

Well MT21 is back and as lesarnmt FA in 10 years.

I see Hawrmis boys are busy on ADVFN ,

Nothing new, more companys are adavnced in treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Why make out Lupuzor is able to treat CIPD and a break through, when so far behind -hizentra and its FDA approved

FDA and EU Approved

https://www.medscape.com/viewarticle/885924
KYOTO, Japan — Subcutaneous (SC) immunoglobulin offers several benefits compared with intravenous (IV) infusion as maintenance treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), including medical, personal, and possibly financial advantages, a new study suggests.

IV immunoglobulin is an established treatment for CIDP, but infusions have to be administered by a healthcare professional whereas at-home treatment with SC immunoglobulin can offer increased autonomy, convenience, and quality of life for patients, as well as potential cost savings. The SC route may also provide more stable immunoglobulin levels.

However, weekly SC administration has not previously been studied in CIDP in an adequately powered randomized clinical trial with appropriate disability outcome measures, said Ivo van Schaik, MD, PhD, University of Amsterdam Academic Medical Center, the Netherlands, so the Polyneuropathy and Treatment with Hizentra (PATH) trial (NCT01545076) trial was designed for this purpose.
The results were presented here at the XXIII World Congress of Neurology.

https://www.cslbehring.com/vita/newsroom/20180315-hizentra-approved-for-cidp-in-europe
FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP
16 Mar 2018

March 16, 2018 – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) approved Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) as the first and only subcutaneous immunoglobulin (SCIg) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment. The approval was based on data from the Phase III PATH (Polyneuropathy And Treatment with Hizentra) study, which is the largest controlled clinical study in CIDP patients to date. CIDP is a rare autoimmune disorder that affects the peripheral nerves and may cause permanent nerve damage.

“This new FDA approval for Hizentra marks a pivotal milestone for patients struggling with the disabling neurological effects of CIDP,” said Dr. Andrew Cuthbertson, Chief Scientific Officer and R&D Director, CSL Limited. “As the first and only subcutaneous immunoglobulin therapy approved to treat CIDP, and studied in the largest controlled clinical trial for CIDP, Hizentra offers patients a more convenient treatment option with proven efficacy and the flexibility and freedom to self-

Broadford B. DNO had and ha ve 0% tax on there PSC no CBP =BUNGS) When Genel had PSC adjusted on There share of Tawke the tax and CBP were removed, but not on any other PSC they held. Take it further, there was no CPB or TAX on Taq Taq when they tookj mit on in January 2001 as an existing oil field. There was no CBP or Tax applied when Addax took on there percentage of Taq Taq and prior to that when Heritage oil took a share of Taq taq in 2004 there was no tax of CBP., but Heritage part of the PSC was hidden from view, but was found in 2005. When Addax sold there share of the PSC to Sinopec with Addax other assets in Africa , there was no Tax or CBP and there is no Tax of CBP on Sinpoec sharte now. In March 2009 when Genel took part of Tawke in a back handed deal that the crook hawrmi arranged they had no Tax of CBP neither did Etamic, that was added after the signature to the PSC and Genel were so out on a limb when insider trading with Hawrmi and Heritage, Hawrmi was able to apply a 30% Tax CBP across all PSC's they held. GKP took on the 40% Hawrmi CBP bung,s and OMV took on 45% BUNBG CBP Tax, and Heritage did a back handed deal to Genel where the KDP picked up over $300 million on Miran, that had already given the KRG MNR some $3 billion in transactions between IOC and People. TKI 5 % dressed up but held by in part by Hawrmi and DNO RAK ex GKP man, it would suit all if DNO took on GKP SH block, but will they take it with such a CBP and Tax, plus , they open themsleves upto extra scrutiny by Regulators. Hard for anyone to explain how GKP are still allowed to trade on the LSE , and no matter what the Government says about making it a rule of law all companys owned and registered in british oversease territorys, it wont happen, as they hold the jurisdiction not the UK and the UK government cant open them to public scrutiniy unless each Government and Judicary in for instance "Burmuda" agree . And with all OFC's they can be run through many other Jurisdictions an are. WZR had CBP and TAX spread about through various parties of the KRG MNR and all were paid well and Hawrmi and the KRG picked up 20% that was routed through local contractors and the local contractors were handsomelly paid. I doubt that is the ned of that though, as legal implications of one contractor are still in play and the sale to Crest does not halt the people involved in WZR holders, or how much oil was pumped and goes directions that suit Hawrami and those surrounding the PUK all Talabanis and Iraq's who were and are members of the INC that was set up in London and is now a big organisation across 4 UK cities and in Think Tanks ... GL to those who hold onto Kurd oil IOC's you need it and so much as changed since March/April 2012 and the likes of companys that were wound up in March 2012 that were close to A Kozel , who felt so hard done by when she also shafted shareholders

Biggest load of BS going. Pro sunny state, how ? When the population prior to 2003 was 70% Shia. As the K24 its a rag to rag of garbage and crooks paper, some of its contant comes from a street in the UK where they practice the Kurd cam of selling counterfit fags out of shops and they try to bribe UK police offices with £5k a month to stay away and they residents of the street keep everyone out, all races are not allowed in only KDP PUK kurds..Thats how far your KRG crooks operate in parts of the uk. Only last month the French rounded up 400 KRG Kurd smuggling groups who smuggle kurds into the UK to assist in illegal practices .. time the UK hammered the KRG and MPs for not acting and calling out the KRG in the UK for there actions, the French are acting to stop these crooks

FDA and EU Approved https://www.medscape.com/viewarticle/885924 KYOTO, Japan — Subcutaneous (SC) immunoglobulin offers several benefits compared with intravenous (IV) infusion as maintenance treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), including medical, personal, and possibly financial advantages, a new study suggests. IV immunoglobulin is an established treatment for CIDP, but infusions have to be administered by a healthcare professional whereas at-home treatment with SC immunoglobulin can offer increased autonomy, convenience, and quality of life for patients, as well as potential cost savings. The SC route may also provide more stable immunoglobulin levels. However, weekly SC administration has not previously been studied in CIDP in an adequately powered randomized clinical trial with appropriate disability outcome measures, said Ivo van Schaik, MD, PhD, University of Amsterdam Academic Medical Center, the Netherlands, so the Polyneuropathy and Treatment with Hizentra (PATH) trial (NCT01545076) trial was designed for this purpose. The results were presented here at the XXIII World Congress of Neurology. https://www.cslbehring.com/vita/newsroom/20180315-hizentra-approved-for-cidp-in-europe FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP 16 Mar 2018 March 16, 2018 – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) approved Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) as the first and only subcutaneous immunoglobulin (SCIg) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment. The approval was based on data from the Phase III PATH (Polyneuropathy And Treatment with Hizentra) study, which is the largest controlled clinical study in CIDP patients to date. CIDP is a rare autoimmune disorder that affects the peripheral nerves and may cause permanent nerve damage. “This new FDA approval for Hizentra marks a pivotal milestone for patients struggling with the disabling neurological effects of CIDP,” said Dr. Andrew Cuthbertson, Chief Scientific Officer and R&D Director, CSL Limited. “As the first and only subcutaneous immunoglobulin therapy approved to treat CIDP, and studied in the largest controlled clinical trial for CIDP, Hizentra offers patients a more convenient treatment option with proven efficacy and the flexibility and freedom to self-infuse at home. CSL Behring is deeply committed to delivering innovative therapies to patients with rare and serious diseases like CIDP, and today we are proud to now offer a

FDA, Suggest you read about BTG Groups "Elevair" BTG will continue to work with the FDA during its review process and will seek to address the specific concerns raised by the Panel.

While all news is wlecomed, what IS IMM doing with its avatars on here, and Finncrap. The aticles published that is put out otday by IMM was published 5 days ago, so is S Muller desperate to get the share price up ? Its not a professional approach by the Company and shows it lack governance https://www.sciencedirect.com/science/article/pii/S0896841118302361?via%3Dihub

mnawaz . Aavtar made up for a puprose? slip out of woodwork An Idiot post if ever there was one, who do you work for? No understanding of anything at all. Fast track by FDA. If you even study GBV then you may understand, XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Components to a disease process . https://www.boehringer-ingelheim.com/press-release/phase-ii-trial-now-enrolling-patients-lupus-nephritis?itid=Boehringer%20Ingelheim%20Phase%20II%20trial%20now%20enrolling%20patients%20with%20the%20kidney%20disease%20Lupus%20Nephritis%0A Nice to see the positive effects of the drug are able to be used in other autimmune condintion . GLA

So its an areticle based on a spurious site, as for twitter account?? What ever the merits of articles , there is no authors name attributed to the article. Medical professionals who treat SLE and work on new treatments are cautious by nature, and FDA approval is key . Finncap have no Medical professsional with qualification in treating SLE, no Scientists, or academics, , no Immunologists. so the report can only be read as promotionla by a company that promotes aims buisness, that as no regulation. The abvove is not to say IMM Lupus drug will not change people lives, but it failed it phase three trial, while making siginificant adavnces, it still failed and applied for a the rights to distrubute the drug for a futher 6 months to the people who were on trial. I hope it will progress, every major Drug company will already have all the data to make decisons. BMS, GSK, AZ do extreme vetting on all drugs that go to trail, as the medical industry works together

Elegance. K3VMC. My question was a simple one and not to irritate or cause offense. Many drugs are on trial for numerous Autoimmune diseases and the cross over between Autoimmune to Nuerological and Rhema, is vast and most Medical University Hospitals worldwide usually find a patient as more than one disease process-I am all for anything that improves and extends a persons life. The reason I ask if its had Full FDA clearence was a simple one, as then it is able to be used by Americans who Assurance providers can not refuse to cover the costs. With GSK having a lience on a drug is a start, but getting other companys like IMM drug to market is important in reducing costs and making Universal Health care systems take it on board and use it, but at the end of the day, its one of a number of treatments SLE paitents will require- as to remmission , its brillinat when it occurs, but its not always long term and a lot pf paitents with many SLE , as an example can go into remmission without any treatment and for unkown reasons. Bio Similar drugs are now being provided in the market place by the likes of Samsung for other disease- so the more compition, the better and the more drugs that can get FDA approval helps amor ethan most realize . Many drugs that dont make it , do go into the Orphan drug catergory, and prevail with outside backers- so no drug is ever dead and wont make it, sometimes it takes longer. gla

K3VMC Does Lupuzor have full FDA approvak and clearence to be sold and precsribed by Every medical Hospital that treats SLE Paitents? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440101/

Hope the new trial drugs will become more effective. Overlap sydrom is one of the challenges faced when tragting a specific diesea , as you will be aware , many autoimmune disease and neurologigal disease overlap and one can easily turn to another , as well as misdiagnosis, which many Rheumatologist make in the UK and elsewhere. Most specialists are stil learning and finding out what triggers over disease that overlap Lupus (SLE) Basic overview https://smhttp-ssl-67430.nexcesscdn.net/page/-/files/pdf/Withers%20%20Lupus%20Overlap%20Syndromes_4.pdf TMA https://www.myositis.org/about-myositis/complications/overlapping-autoimmune-diseases/ Inflammatory myopathies COME UNDER NEUROMUSCULAR , but also form part of Autoimmune and Rheumatological. Bristol Myers Squibb RD in New Jersey as trails with John Hopikins and Cleveland C, running I believe? Not sure its common knowldge , try there website SLE as many components as you know. Many drugs also finish up in Orphan drug catergory, where they are still brought to conclusion no matter how small a company or its targeted use, as you say some find there way to be used in other diseases. I have hold some of these are the price dropped a few weeks back, but due to R/D at JohnHopkins trailing a another drug with Bristol Myers. https://www.bms.com/researchers-and-partners/in-the-pipeline.html Good luck all

TSH. Call it a Hobby, Call it work, Call it ongoing, as for dominoes or such like, you are free to do what ever you wish. Enjoy the sunshine with your beer or tea? mate

You are clueless and dont bsee the correlation . Well Taff, you have now shown how much of a teapot you are